S}FN%-.HLL!I45&62}|ZM';3[(}U-2B[{ZL&LNM=J^?~W@M
SYSTEM PROCESSING...
S}FN%-.HLL!I45&62}|ZM';3[(}U-2B[{ZL&LNM=J^?~W@M
SYSTEM PROCESSING...
Posted: 2025-04-16 21:31:45 UTC
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
Status
Last Updated
2025-04-16 21:32:14 UTC
Verified By
Rollup News
A trial in the Democratic Republic of Congo found that tecovirimat did not significantly speed up the resolution of mpox lesions compared to placebo in patients with clade I MPXV infection.
Tecovirimat's effectiveness in treating mpox
Clinical trial results in the Democratic Republic of Congo
Comparison of tecovirimat versus placebo for mpox lesion resolution
Implications for mpox treatment strategies
Determining effective therapies for mpox
Tecovirimat did not lead to faster resolution of mpox lesions than placebo